Tadliq is a drug owned by Cmp Development Llc. It is protected by 3 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 24, 2038. Details of Tadliq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11975006 | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | Active |
| US11382917 | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | Active |
| US11666576 | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tadliq's patents.
Latest Legal Activities on Tadliq's Patents
Given below is the list of recent legal activities going on the following patents of Tadliq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 06 Jun, 2023 | US11666576 |
| Mail Patent eGrant Notification | 06 Jun, 2023 | US11666576 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Jun, 2023 | US11666576 |
| Recordation of Patent Grant Mailed Critical | 06 Jun, 2023 | US11666576 |
| Electronic Review Critical | 06 Jun, 2023 | US11666576 |
| Recordation of Patent eGrant | 06 Jun, 2023 | US11666576 |
| Patent eGrant Notification | 06 Jun, 2023 | US11666576 |
| Email Notification Critical | 18 May, 2023 | US11666576 |
| Electronic Review Critical | 18 May, 2023 | US11666576 |
| Issue Notification Mailed Critical | 17 May, 2023 | US11666576 |
US patents provide insights into the exclusivity only within the United States, but Tadliq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tadliq's family patents as well as insights into ongoing legal events on those patents.
Tadliq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tadliq's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 24, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tadliq Generic API suppliers:
Tadalafil is the generic name for the brand Tadliq. 29 different companies have already filed for the generic of Tadliq, with Macleods Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tadliq's generic
Alternative Brands for Tadliq
Tadliq which is used for improving exercise ability in patients with Pulmonary Arterial Hypertension (PAH)., has several other brand drugs using the same active ingredient (Tadalafil). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tadalafil, Tadliq's active ingredient. Check the complete list of approved generic manufacturers for Tadliq
About Tadliq
Tadliq is a drug owned by Cmp Development Llc. It is used for improving exercise ability in patients with Pulmonary Arterial Hypertension (PAH). Tadliq uses Tadalafil as an active ingredient. Tadliq was launched by Cmp Dev Llc in 2022.
Approval Date:
Tadliq was approved by FDA for market use on 17 June, 2022.
Active Ingredient:
Tadliq uses Tadalafil as the active ingredient. Check out other Drugs and Companies using Tadalafil ingredient
Treatment:
Tadliq is used for improving exercise ability in patients with Pulmonary Arterial Hypertension (PAH).
Dosage:
Tadliq is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/5ML | SUSPENSION | Prescription | ORAL |